- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic obstructive pulmonary disease
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 OOS June 2023 PBAC Meeting - (PDF 351KB)
- Public Summary Document (PSD) November 2022 OOS June 2023 PBAC Meeting - (Word 665KB)
Budesonide with glycopyrronium and formoterol – November 2022
Budesonide with Glycopyrronium and Formoterol: Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses; Breztri Aerosphere® DFP-EvoCap – November 2022 – OOS June 2023 PBAC Meetings
Last updated
24 July 2023